🚀 VC round data is live in beta, check it out!
Bolt Biotherapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Bolt Biotherapeutics and similar public comparables like Stenocare, CalciMedica, Addex Therapeutics, Iterum Therapeutics and more.
Bolt Biotherapeutics Overview
About Bolt Biotherapeutics
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
Founded
2015
HQ
Employees
52
Website
Sectors
Financials (LTM)
EV
$585K
Bolt Biotherapeutics Financials
Bolt Biotherapeutics reported last 12-month revenue of $7M.
In the same LTM period, Bolt Biotherapeutics generated had net loss of ($36M).
Revenue (LTM)
Bolt Biotherapeutics P&L
In the most recent fiscal year, Bolt Biotherapeutics reported revenue of $8M and EBITDA of ($33M).
Bolt Biotherapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $7M | XXX | $8M | XXX | XXX | XXX |
| EBITDA | — | XXX | ($33M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (433%) | XXX | XXX | XXX |
| EBIT Margin | (576%) | XXX | (450%) | XXX | XXX | XXX |
| Net Profit | ($36M) | XXX | ($33M) | XXX | XXX | XXX |
| Net Margin | (546%) | XXX | (434%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Bolt Biotherapeutics Stock Performance
Bolt Biotherapeutics has current market cap of $9M, and enterprise value of $585K.
Market Cap Evolution
Bolt Biotherapeutics' stock price is $4.64.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $585K | $9M | 0.0% | XXX | XXX | XXX | $-17.39 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBolt Biotherapeutics Valuation Multiples
Bolt Biotherapeutics trades at 0.1x EV/Revenue multiple, and (0.0x) EV/EBITDA.
EV / Revenue (LTM)
Bolt Biotherapeutics Financial Valuation Multiples
As of March 30, 2026, Bolt Biotherapeutics has market cap of $9M and EV of $585K.
Equity research analysts estimate Bolt Biotherapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bolt Biotherapeutics has a P/E ratio of (0.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9M | XXX | $9M | XXX | XXX | XXX |
| EV (current) | $585K | XXX | $585K | XXX | XXX | XXX |
| EV/Revenue | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.0x) | XXX | XXX | XXX |
| EV/EBIT | (0.0x) | XXX | (0.0x) | XXX | XXX | XXX |
| P/E | (0.2x) | XXX | (0.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Bolt Biotherapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Bolt Biotherapeutics Margins & Growth Rates
Bolt Biotherapeutics' revenue in the last 12 month declined by (39%).
Bolt Biotherapeutics' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.8M for the same period.
Bolt Biotherapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (39%) | XXX | (61%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (433%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (50%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 215% | XXX | 179% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 457% | XXX | 371% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 550% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Bolt Biotherapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Stenocare | XXX | XXX | XXX | XXX | XXX | XXX |
| CalciMedica | XXX | XXX | XXX | XXX | XXX | XXX |
| Addex Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Iterum Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| OncoZenge | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bolt Biotherapeutics M&A Activity
Bolt Biotherapeutics acquired XXX companies to date.
Last acquisition by Bolt Biotherapeutics was on XXXXXXXX, XXXXX. Bolt Biotherapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Bolt Biotherapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBolt Biotherapeutics Investment Activity
Bolt Biotherapeutics invested in XXX companies to date.
Bolt Biotherapeutics made its latest investment on XXXXXXXX, XXXXX. Bolt Biotherapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Bolt Biotherapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Bolt Biotherapeutics
| When was Bolt Biotherapeutics founded? | Bolt Biotherapeutics was founded in 2015. |
| Where is Bolt Biotherapeutics headquartered? | Bolt Biotherapeutics is headquartered in United States. |
| How many employees does Bolt Biotherapeutics have? | As of today, Bolt Biotherapeutics has over 52 employees. |
| Who is the CEO of Bolt Biotherapeutics? | Bolt Biotherapeutics' CEO is William P. Quinn. |
| Is Bolt Biotherapeutics publicly listed? | Yes, Bolt Biotherapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Bolt Biotherapeutics? | Bolt Biotherapeutics trades under BOLT ticker. |
| When did Bolt Biotherapeutics go public? | Bolt Biotherapeutics went public in 2021. |
| Who are competitors of Bolt Biotherapeutics? | Bolt Biotherapeutics main competitors are Stenocare, CalciMedica, Addex Therapeutics, Iterum Therapeutics. |
| What is the current market cap of Bolt Biotherapeutics? | Bolt Biotherapeutics' current market cap is $9M. |
| What is the current revenue of Bolt Biotherapeutics? | Bolt Biotherapeutics' last 12 months revenue is $7M. |
| What is the current revenue growth of Bolt Biotherapeutics? | Bolt Biotherapeutics revenue growth (NTM/LTM) is (39%). |
| What is the current EV/Revenue multiple of Bolt Biotherapeutics? | Current revenue multiple of Bolt Biotherapeutics is 0.1x. |
| Is Bolt Biotherapeutics profitable? | No, Bolt Biotherapeutics is not profitable. |
| What is the current net income of Bolt Biotherapeutics? | Bolt Biotherapeutics' last 12 months net income is ($36M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.